MedTrace Logo

Full Spectrum Hemp Observational Study

NCT04730414 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-02-01

No results posted yet for this study

Summary

In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.

Conditions

  • Acne Vulgaris
  • Acne Vulgaris Superficial Mixed Comedonal and Inflammatory

Interventions

DRUG

Full-spectrum hemp (0.018% THC)

Topical Application

Sponsors & Collaborators

  • Charlotte's Web, Inc

    lead INDUSTRY

Principal Investigators

  • Jeff Lokken · Charlottes Web, Inc

Eligibility

Min Age
13 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04730414 on ClinicalTrials.gov